Loading...
OTCM
AIMI
Market cap3mUSD
Jun 10, Last price  
0.07USD
Name

AIM ImmunoTech Inc

Chart & Performance

D1W1MN
P/E
—
P/S
20.65
EPS
—
Div Yield, %
—
Shrs. gr., 5y
72.73%
Rev. gr., 5y
3.96%
Revenues
170k
-15.84%
1,083,000933,0001,059,000265,000111,000135,000161,000213,000150,000197,000133,00092,000437,000367,000140,000163,000135,000141,000202,000170,000
Net income
-17m
L-40.20%
-13,213,000-19,399,000-18,139,000-12,219,000-13,438,000-13,136,000-9,015,000-17,354,000-16,225,000-17,450,000-15,230,000-7,502,000-8,259,000-9,813,000-10,826,000-16,258,000-21,513,000-21,086,000-28,962,000-17,320,000
CFO
-15m
L-29.99%
-7,236,000-13,747,000-15,112,000-9,358,000-9,297,000-11,886,000-10,096,000-13,136,000-16,830,000-13,918,000-16,053,000-7,380,000-7,941,000-10,640,000-9,067,000-10,368,000-13,965,000-16,108,000-21,267,000-14,888,000
Earnings
Aug 14, 2025

Profile

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
URL
https://aimimmuno.com/
IPO date
Jul 12, 1996
Employees
22
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
170
-15.84%
202
43.26%
141
4.44%
Cost of revenue
19,942
32,118
39,987
Unusual Expense (Income)
NOPBT
(19,772)
(31,916)
(39,846)
NOPBT Margin
Operating Taxes
1,641
Tax Rate
NOPAT
(19,772)
(31,916)
(41,487)
Net income
(17,320)
-40.20%
(28,962)
37.35%
(21,086)
-1.98%
Dividends
Dividend yield
Proceeds from repurchase of equity
892
485
80
BB yield
-8.04%
-2.27%
-0.53%
Debt
Debt current
2,546
446
178
Long-term debt
1,029
1,213
1,496
Deferred revenue
Other long-term liabilities
(29,431)
Net debt
(402)
(11,411)
(1,967)
Cash flow
Cash from operating activities
(14,888)
(21,267)
(16,108)
CAPEX
(18)
(271)
Cash from investing activities
4,706
(832)
10,988
Cash from financing activities
6,444
485
80
FCF
(16,861)
(30,768)
(37,954)
Balance
Cash
3,977
13,070
34,190
Long term investments
(30,549)
Excess cash
3,968
13,060
3,634
Stockholders' equity
(408,770)
(379,802)
Invested Capital
1,619
419,945
389,676
ROIC
ROCE
EV
Common stock shares outstanding
56,017
48,585
48,047
Price
0.20
-54.99%
0.44
41.04%
0.31
-66.10%
Market cap
11,091
-48.11%
21,373
42.62%
14,986
-65.59%
EV
10,689
10,651
13,715
EBITDA
(19,526)
(31,678)
(39,590)
EV/EBITDA
Interest
585
478
Interest/NOPBT